Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
Mucinous peritoneal metastases (PM) generally respond poorly to systemic treatment, and there is a clear unmet need for new treatment strategies to improve survival and quality of life for patients with PM. In this work, the growth inhibitory effect of five drugs (oxaliplatin (OXA; 5 mg/kg), irinote...
Main Authors: | Karianne Giller Fleten, Christin Lund-Andersen, Stein Waagene, Torveig Weum Abrahamsen, Yrr Mørch, Kjetil Boye, Annette Torgunrud, Kjersti Flatmark |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-08-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320302977 |
Similar Items
-
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
by: Schee Kristina, et al.
Published: (2012-11-01) -
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale
by: Yvonne Andersson, et al.
Published: (2021-06-01) -
Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.
by: Anne Hansen Ree, et al.
Published: (2012-01-01) -
Peritoneal metastases from mucinous endocervical adenocarcinoma
by: Paul H. Sugarbaker, et al.
Published: (2014-12-01) -
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
by: Anne Hansen Ree, et al.
Published: (2014-01-01)